Haleon PLC Sponsored ADR
HLN Healthcare Drug Manufacturers Specialty & Generic
Haleon PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $14.5 billion, up 1.33% from fiscal 2024. Revenue growth for three consecutive years, operating cash flow growth for three.
Follow HLN
Haleon PLC Sponsored ADR (HLN) EV/Sales
As of 16 October 2026, Haleon PLC Sponsored ADR (HLN) trades at a EV/Sales of 3.1×. Over the past ten years it has ranged from 0.0× (March 2024) to 3.5× (June 2025); the current reading is higher than 83% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.1× | 4.66% |
| FY2024 | 3.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2024 | 3.3× | 18.19% |
| Mar 2024 | 2.8× | — |
| Sep 2023 | 0.0× | — |
| Jun 2023 | 0.0× | — |
| 1 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VTRS Viatris Inc. compare | 2.3× |
| RDY Dr. Reddy's Laboratories Ltd compare | 2.9× |
| TAK Takeda Pharmaceutical Co. compare | 3.0× |
| ELAN Elanco Animal Health Incorporated compare | 3.0× |
| HLN Haleon PLC Sponsored ADR | 3.1× |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 3.5× |
| NBIX Neurocrine Biosciences, Inc. compare | 4.1× |
| ZTS Zoetis Inc. compare | 4.4× |
| UTHR United Therapeutics Corporation compare | 6.5× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)